In todayโs ever-evolving and highly regulated pharmaceutical landscape, managing regulatory affairs (RA) and pharmacovigilance (PV) has become a critical and resource-intensive responsibility.
Patient safety is a crucial part of healthcare that seeks to protect patients from harm during their treatment and care.
21 CFR 314.80 is a regulation established by the U.S. Food and Drug Administration (FDA) to govern the post marketing reporting of adverse drug experiences.
Adaptis is delighted to announce the signing of a Memorandum of Understanding (MoU) with Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune. This partnership aims to bridge the gap between academia and industry, fostering collaboration and expertise in the pharmaceutical sector.
With immense gratitude and joy, we celebrated the inauguration of our new officeโa milestone made possible by unwavering support and blessings. The pooja and lamp-lighting ceremony symbolized the start of a journey filled with hope, unity, and ambition.
We are thrilled to have played a pivotal role in helping our client successfully clear their USFDA audit. Through our PV expertise in designing and implementing comprehensive Pharmacovigilance systems, strengthening SOP frameworks, and ensuring rigorous PV compliance...
๐จ ๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐ ๐๐๐ ๐ ๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐! From our humble beginnings to 5 years of ๐ซ๐๐ฌ๐ข๐ฅ๐ข๐๐ง๐๐, ๐ข๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง, ๐๐ง๐ ๐ฉ๐ฎ๐ซ๐ฉ๐จ๐ฌ๐-๐๐ซ๐ข๐ฏ๐๐ง ๐ ๐ซ๐จ๐ฐ๐ญ๐ก, this journey has been truly special. A heartfelt thank you to our ๐ข๐ง๐๐ซ๐๐๐ข๐๐ฅ๐ ๐ญ๐๐๐ฆ, ๐ฏ๐ข๐ฌ๐ข๐จ๐ง๐๐ซ๐ฒ ๐ฅ๐๐๐๐๐ซ๐ฌ, ๐ญ๐ซ๐ฎ๐ฌ๐ญ๐๐ ๐๐ฅ๐ข๐๐ง๐ญ๐ฌ, ๐๐ง๐ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐ฉ๐๐ซ๐ญ๐ง๐๐ซ๐ฌ who made this day possible...
During Iphex 2025, our team engaged in insightful discussions and strategic networking with international partners. We highlighted Adaptisโ expertise in Pharmacovigilance and Regulatory Affairs, demonstrating how we empower organizations to achieve regulatory compliance, foster innovation, and drive sustainable growth across global markets.
Chat with us!
